12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Prednisone: Phase III discontinued

Researchers at the university and colleagues stopped the double-blind, U.S. Phase III PANTHER-IPF trial after an interim analysis of 155 patients showed that compared to placebo (n=78), the oral combination of prednisone, azathioprine and N-acetylcysteine (n=77), a widely used treatment for IPF according to the researchers, led to significantly greater rates of death (10%...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >